Current Report Filing (8-k)
August 11 2022 - 3:01PM
Edgar (US Regulatory)
0001630113
false
0001630113
2022-08-05
2022-08-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): August 5, 2022
BIOTRICITY
INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
001-40761 |
|
47-2548273 |
(State
or Other Jurisdiction of
Incorporation
or Organization) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
275
Shoreline Drive, Suite 150
Redwood
City, California 94065
(Address
of Principal Executive Offices)
(650)
832-1626
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b):
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value
$0.001 per share |
|
BTCY |
|
NASDAQ Capital Markets |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
August 5, 2022, Patricia Kennedy as a member of the Board of Directors of Biotricity Inc. (the “Company”), a member of the
Company’s Audit Committee, and a member of the Company’s Nominating and Corporate Governance Committee, resigned from the
Company’s Board of Directors effective August 5, 2022. Patricia Kennedy did not advise the Company of any disagreement with the
Company on any matter relating to its operations, policies or practices.
On
August 5, 2022, Norman Betts as a member of the Board of Directors of Biotricity Inc. (the “Company”) and a member of the
Company’s Audit Committee, resigned from the Company’s Board of Directors effective August 5, 2022. Norman Betts did not
advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.
On
August 11, 2022, the Board of Directors of the Company appointed Chester White to the Board of Directors to fill the vacancy created
by Patricia Kennedy’s resignation. There are no arrangements or understandings between Mr. White and any other persons pursuant
to which he was selected as a director. Mr. White will receive compensation as a non-employee director in accordance with the company’s
non-employee director compensation practice. Mr. White has no direct or indirect material interest in any transaction required to be
disclosed pursuant to Item 404(a) of Regulation S-K. Mr. White has not yet been appointed to any committees of the Board of Directors.
Mr.
White is a performance driven executive with leadership in fund management, venture capital, private equity, hedge funds, investment
banking, mergers and acquisitions, strategy consulting, and technology innovation (AI, blockchain, cyber, mobile, cloud, enterprise software,
robotics, automation, healthcare). Mr. White holds hands on experience across a spectrum of functions (investment, board level, strategic.
operations, and restructurings) and size (startup to fortune 500, private and public).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date:
August 11, 2022
|
BIOTRICITY INC. |
|
|
|
|
By: |
/s/
Waqaas Al-Siddiq |
|
|
Waqaas Al-Siddiq |
|
|
Chief Executive Officer |
Biotricity (NASDAQ:BTCY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biotricity (NASDAQ:BTCY)
Historical Stock Chart
From Oct 2023 to Oct 2024